URLi ISRs Could Sting LLY; Ph3 Results Mixed

Lilly presented results from its two ultra-rapid-acting lispro (URLi) pivotal trials, PRONTO-T1D and PRONTO-T2D. Below, FENIX provides an overview of the data as well as thoughts on the imbalance in injection site reactions (ISRs) with URLi and the potential market implications.

About The Author

Matthew Maryniak

President of Fenix Group International

Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.

If you receive our email blasts, you already have an account.

Purchase Blast$599.00

You can read the article’s full content online after purchase.